Literature DB >> 27306912

Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study.

Josep Porta-Sales1, Cristina Garzón-Rodríguez2, Christian Villavicencio-Chávez2, Silvia Llorens-Torromé2, Jesús González-Barboteo3.   

Abstract

INTRODUCTION: Most clinical reports on methadone rotation describe outcomes in hospitalized patients. The few studies that have included outpatients are retrospective. The aim of this study was to assess the efficacy and safety of methadone as a second-line opioid in adult patients with advanced cancer after rotation in routine clinical practice at a palliative care outpatient clinic. PATIENTS AND METHODS: This was a prospective, open-label study of 145 patients whose treatment was rotated from other opioids to methadone. Informed consent was obtained in all cases. The main outcome measure was change in the variable "worst pain" at day 28. Pain and pain interference were assessed with the Brief Pain Inventory, with side effects evaluated according to the Common Terminology Criteria for Adverse Events version 3.0. Pain levels were evaluated at study entry and at days 3, 7, 9, 14, 21, and 28.
RESULTS: Rotation to methadone was performed for the following reasons: poor pain control (77.9%), opioid side effects (2.1%), or both (20%). The mean daily oral morphine equivalent dose before rotation was 193.7 mg. The median worst and average pain scores decreased significantly (p < .0001) from baseline to day 28: The median worst pain score decreased from 9 (interquartile range [IQR]: 8-10) to 6 (IQR: 3-8), and the median average pain score decreased from 6 (IQR: 5-7) to 4 (IQR: 2-5). The proportions of patients with moderate to severe worst and average pain decreased by 30.3% and 47.5%, respectively, by day 28. No increase in opioid toxicity was observed during the study.
CONCLUSION: In outpatients with advanced cancer, rotation to methadone as a second-line opioid was efficacious and safe when using a tiered scheme with close follow-up by experienced health professionals. IMPLICATIONS FOR PRACTICE: The results of this study, conducted prospectively under real clinical conditions, support the efficacy and safety of oral methadone as a second-line opioid in ambulatory patients with cancer. Moreover, these findings corroborate previously reported outcomes in retrospective outpatient studies and prospective studies that evaluated inpatient populations. Although more research into methadone rotation strategies is still needed, this study describes a successful tiered scheme of oral methadone rotation that was proven safe and effective during follow-up. ©AlphaMed Press.

Entities:  

Keywords:  Ambulatory care; Methadone; Neoplasms; Outpatient; Pain; Palliative care; Palliative medicine

Mesh:

Substances:

Year:  2016        PMID: 27306912      PMCID: PMC4978552          DOI: 10.1634/theoncologist.2015-0503

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  45 in total

Review 1.  WITHDRAWN: Opioid switching to improve pain relief and drug tolerability.

Authors:  Columba Quigley
Journal:  Cochrane Database Syst Rev       Date:  2013-10-18

2.  Methadone initiation and rotation in the outpatient setting for patients with cancer pain.

Authors:  Henrique A Parsons; Maxine de la Cruz; Badi El Osta; Zhijun Li; Bianca Calderon; J Lynn Palmer; Eduardo Bruera
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

3.  Palliative performance scale (PPS): a new tool.

Authors:  F Anderson; G M Downing; J Hill; L Casorso; N Lerch
Journal:  J Palliat Care       Date:  1996       Impact factor: 2.250

4.  Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.

Authors:  S Ahmedzai; D Brooks
Journal:  J Pain Symptom Manage       Date:  1997-05       Impact factor: 3.612

Review 5.  Methadone--metabolism, pharmacokinetics and interactions.

Authors:  Anna Ferrari; Ciro Pio Rosario Coccia; Alfio Bertolini; Emilio Sternieri
Journal:  Pharmacol Res       Date:  2004-12       Impact factor: 7.658

6.  The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study.

Authors:  Sebastiano Mercadante; Patrizia Ferrera; Edoardo Arcuri
Journal:  Support Care Cancer       Date:  2010-09-30       Impact factor: 3.603

Review 7.  A systematic review of opioid conversion ratios used with methadone for the treatment of pain.

Authors:  Douglas J Weschules; Kevin T Bain
Journal:  Pain Med       Date:  2008-06-28       Impact factor: 3.750

Review 8.  The role of methadone in cancer pain treatment--a review.

Authors:  W Leppert
Journal:  Int J Clin Pract       Date:  2009-07       Impact factor: 2.503

Review 9.  High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.

Authors:  J Säwe
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

10.  Opioid switching in patients with advanced cancer followed at home. A retrospective analysis.

Authors:  Sebastiano Mercadante; Alessandro Valle; Giampiero Porzio; Flavio Fusco; Federica Aielli; Claudio Adile; Alessandra Casuccio
Journal:  J Pain Symptom Manage       Date:  2012-10-25       Impact factor: 3.612

View more
  9 in total

Review 1.  Best Practices in the Management of Nonmedical Opioid Use in Patients with Cancer-Related Pain.

Authors:  Esad Ulker; Egidio Del Fabbro
Journal:  Oncologist       Date:  2019-12-24

Review 2.  Methadone for Pain Management: A Pharmacotherapeutic Review.

Authors:  Denise Kreutzwiser; Qutaiba A Tawfic
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

3.  The role of methadone in cancer-induced bone pain: a retrospective cohort study.

Authors:  Merlina Sulistio; Robert Wojnar; Seraphina Key; Justin Kwok; Ziad Al-Rubaie; Natasha Michael
Journal:  Support Care Cancer       Date:  2020-07-06       Impact factor: 3.603

4.  Malignant psoas syndrome associated with gynecological malignancy: Three case reports and a review of the literature.

Authors:  Shiro Takamatsu; Kosuke Murakami; Hisamitsu Takaya; Takako Tobiume; Hidekatsu Nakai; Ayako Suzuki; Masaki Mandai; Noriomi Matsumura
Journal:  Mol Clin Oncol       Date:  2018-05-21

5.  Opioid Rotation in Cancer Pain Treatment.

Authors:  Michael Schuster; Oliver Bayer; Florian Heid; Rita Laufenberg-Feldmann
Journal:  Dtsch Arztebl Int       Date:  2018-03-02       Impact factor: 5.594

Review 6.  Multidimensional Treatment of Cancer Pain.

Authors:  Weiyang Christopher Liu; Zhong Xi Zheng; Kian Hian Tan; Gregory J Meredith
Journal:  Curr Oncol Rep       Date:  2017-02       Impact factor: 5.075

Review 7.  How to Use Methadone in an Era of an Opioid Epidemic.

Authors:  Yvonne Heung; Akhila Reddy
Journal:  Curr Treat Options Oncol       Date:  2020-03-19

8.  Methadone as a "Tumor Theralgesic" against Cancer.

Authors:  Marta Michalska; Arndt Katzenwadel; Philipp Wolf
Journal:  Front Pharmacol       Date:  2017-10-31       Impact factor: 5.810

9.  A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer.

Authors:  Gregory M Hermann; Austin J Iovoli; Alexis J Platek; Chong Wang; Austin Miller; Kristopher Attwood; Daniel J Bourgeois; Anurag K Singh
Journal:  Cancer       Date:  2019-12-23       Impact factor: 6.921

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.